Member Area

FarmavitaR+ : Regulatory Affairs Network

Thursday
Mar 11th
Home arrow FarmavitaR+ Journal arrow Business News
Pharmaceutical Business News
Print E-mail
Market Report
Written by Business Insights   
Thursday, 21 January 2010

business-insights-logo_275x48.gif

Biosimilars: Key developments in the regulatory environment

This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. It also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

 

Last Updated ( Thursday, 21 January 2010 )
Read more...
 
Print E-mail
Market Report
Written by Business Insights   
Thursday, 21 January 2010

business-insights-logo_275x48.gif

Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment

This report provides a comprehensive examination of the clinical trial landscape in emerging countries, with specific focus on China, India, Central and Eastern Europe and Latin America. It identifies the major drivers and barriers to conducting clinical trials in emerging regions and profiles key issues for consideration when selecting a trial site.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Read more...
 
Print E-mail
Market Report
Written by Business Insights   
Thursday, 21 January 2010

business-insights-logo_275x48.gif

Key Trends In Drug-diagnostic Co-development: Identifying collaborative opportunities and navigating regulatory challenges

This report explores the potential for applying genomic-based diagnostics to new drug developments, and the resultant implications for the pharma/biotech and diagnostic industries. It also reviews 28 collaborative agreements for the co-development of drug-diagnostics and determines which combinations can be expected to result in commercial products in the near future.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!  

Read more...
 
Print E-mail
Product Report
Written by Business Insights   
Tuesday, 08 December 2009

business-insights-logo_275x48.gif

Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011.

Read more...
 
Print E-mail
Market Report
Written by Business Insights   
Tuesday, 08 December 2009

business-insights-logo_275x48.gif

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.

Read more...
 
Print E-mail
Market Report
Written by Datamonitor   
Tuesday, 08 December 2009

datamonitor_logo.gif

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Read more...
 
Print E-mail
Market Report
Written by Datamonitor   
Tuesday, 14 July 2009

datamonitor_logo.gif

Generic Benchmarking: Brand Erosion at Patent Expiry

Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.

Last Updated ( Tuesday, 08 December 2009 )
Read more...
 
Print E-mail
Market Report
Written by Datamonitor   
Tuesday, 14 July 2009

datamonitor_logo.gif

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Last Updated ( Monday, 14 September 2009 )
Read more...
 
Print E-mail
Market Report
Written by Business Insights   
Tuesday, 14 July 2009

business-insights-logo.gif

Maximizing opportunities towards achieving clinical success

For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery phases of research. This report will describe these technologies, their place in the drug discovery and development paradigm and their value for improving drug safety.

Last Updated ( Monday, 14 September 2009 )
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 1 - 9 of 83
Advertisement
 

3D Content Cloud

BabelFish Translator




Click Flag for Translation

Sponsors

Member Log-in

Log-in to FarmavitaR+ community & network Membership is FREE!

Who's Online

Track Site Updates

Update me when site is updated

Subscribe to RSS


Regulatory Affairs

RA Section

Reports

Click to Reports

Events

Click to Events

Groups

Groups